TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CFO James Emmett Young acquired 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were bought at an average price of $5.65 per share, with a total value of $33,900.00. Following the acquisition, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at $169,500. The trade was a 25.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

James Emmett Young also recently made the following trade(s):

• On Monday, January 27th, James Emmett Young acquired 24,000 shares of TriSalus Life Sciences stock. The shares were bought at an average price of $5.40 per share, with a total value of $129,600.00.

TriSalus Life Sciences Trading Up 0.9 %

Shares of TLSI traded up $0.05 during mid-day trading on Monday, reaching $5.62. The company's stock had a trading volume of 17,493 shares, compared to its average volume of 30,542. The stock has a market cap of $171.32 million, a PE ratio of -2.26 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 52 week low of $3.50 and a 52 week high of $10.42. The company's fifty day moving average price is $4.70 and its two-hundred day moving average price is $4.73.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds have recently made changes to their positions in the business. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $66,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $92,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $108,000. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC increased its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after buying an additional 62,542 shares during the period. 2.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TLSI has been the subject of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price objective for the company. Roth Mkm reiterated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Northland Capmk upgraded shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday, October 25th. Finally, Northland Securities began coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an "outperform" rating and a $12.50 target price for the company. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.